Substitute for form 1449A/PTO

ſ

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Group Art Unit 1696 1656

Examiner Name Te-Be-Assignant S. Noakes

Attorney Docket Number 58777.000008

			U.S. PATENT DOCUM	MENTS	
Examiner Intiels	Cite No.1	U.S. Petent Document Kind Code <sup>2</sup> Number (if known)	Neme of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevent Figures Appeer
75 <b>9</b> 1.N.7	U1	4,987,070	Magota et al.	01/22/91	
<b>3</b>	U2	5,599,690	Fenton et el.	02/04/97	
SX /	Ų3	5,622,845	Brunner et al.	04/22/97	
V	U4	5,698,418	Brunner et al.	12/16/97	
					-0-11/50
				R	ECEIVED
				-	MAY 1 3 200Z
				TECI	CENTER 1600/2900
1	L				

## Pages, Columns, Lines, Name of Patentee Date of Publication of Cite Where Relevant Passages or Relevant Examiner or Applicant of Cited Document Kind Code<sup>5</sup> Initials' Office<sup>3</sup> Number<sup>4</sup> Cited Document MM-DD-YYYY T<sub>6</sub> (if known) Figures Appear Abstrack.M.N./ F1 JP 61119189 Mizumoto et al 06/06/86 Abstracts M.N. JP 62044198 Hanada 02/26/87 SMN ĒΡ 0683233 A2 Shinobu et al 11/22/95 S.M.N ΕP F4 0164273 A2 Matsuo et al 12/11/85 2079003 6/27/91

FOREIGN PATENT DOCUMENTS

Examiner Signature	/Suzanne M. Noakes/	Date Considered	11/25/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*\*Unique citation designation number.\*\* Sea attached Kinds of U.S. Pattent Documents. \*\*Enter Office that issued the document, by the Northers code (WIPO Standard ST3). \*\*For Japanese pattent documents, bits indication of the year of the riegin of the Emperor must perform the Emperor must promise the serial number of the pattent document. \*\*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.\*\* Applicant is toplace a check mark her if English analguage Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patient and Trademark Chiefe, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patients, Washington, DC 20231.

Sheet 2

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) of 2

Complete if Known Application Number Filing Date First Named Inventor Group Art Unit **Examiner Name** Attorney Docket Number

اي			OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	^
JC98 35	ıminer als *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, dry and/or country where published.	ENTER
/S	.M.N./	P1	TSAI, Larry B. et al., *Control of Misincorporation of <i>De Novo</i> Synthesized Norleucine into Recombinant Interleukin-2 in <i>E. Coli</i> ,* <i>Biochemical and Biophysical Communications</i> , 156(2):733-739 (1988).	
		P2	BOGOSIAN, George, *Biosynthesis and Incorporation into Protein of Norleucine by Escherichia coli,* The Journal of Biological Chemistry, 264(1):531-539 (1989).	E
		P3	APOSTOL, Izydor, et al., "Incorporation of Norvaline at Leucine Positions in Recombinant Humah Hemoglobin Expressed in Escherichia coli." The Journal of Biological Chemistry, 272(46):28980-28988 (1997).	CEN
		P4	KANGAWA, Kenji, et al., "Purification and Complete Amino Acid Sequence of α-Human Atrial Natriuretic Polypeptide (α-hANP)," Biochemical and Biophysical Research Communications, 118(1):131-139 (1984).	TER.
		P5	MASAKI, Takeharu: et al., "Studies on a New Proteolytic Enzyme from Achromobacter Lyticus M4971 II. Specificity and Inhibition Studies of Achromobacter Protease 1," Biochimica et Biophysica Acta, 660:51-55 (1981).	600/2
		P6	NEIDHARDT, Frederick C., et al., "Chemical Composition of <i>Escherichia coli.</i> " <i>Escherichia coli</i> and <i>Salmonella Cellular</i> and <i>Molecular Biology</i> , Vol. I, pp. 13-16, ASM Press, Washington, DC (1996).	200
		P7	TWIGG, Andrea J., et al., "Trans-Complementable Copy-Number Mutants of Plasmid ColE1," Nature, 283:216- 218 (1980).	
-	V	P8	KREDICH, Nicholas M., "Biosynthesis of Cysteine," <i>Escherichia coli and Salmonella Cellular and Molecular Biology</i> , Vol. I, pp.514-527, ASM Press, Washington, DC (1996).	
Tena		P9	VUET, DURAID BLAIT, Blochemissy, Vol. 2, Second Edition, Tokyo Kogaku Dojio, pp. 869,870 (1988)	-
_				T
_				1
				$\vdash$

Considered Signature EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

11/25/2008

/Suzanne M. Noakes/

Examiner

Unique citation designation number, <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burdon Nou's Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chell information Office, U.S. Patent and Talkeria. Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Plantans, Washington, DC 20231.